The impact of sleep loss on performance monitoring and error-monitoring: A systematic review and meta-analysis

2021 ◽  
pp. 101490
Author(s):  
Johanna M. Boardman ◽  
Kate Porcheret ◽  
Jacob W. Clark ◽  
Thomas Andrillon ◽  
Anna W.T. Cai ◽  
...  
Keyword(s):  
Systematic Review ◽  
Performance Monitoring ◽  
Meta Analysis ◽  
Sleep Loss ◽  
Error Monitoring ◽  
The Impact

Response-locked component of error monitoring in psychopathy: A systematic review and meta-analysis of error-related negativity/positivity

2020 ◽  
Author(s):  
William Vallet ◽  
Cecilia Neige ◽  
Sabine MOUCHET-MAGES ◽  
Jerome Brunelin ◽  
Simon Grondin
Keyword(s):  
Systematic Review ◽  
Performance Monitoring ◽  
Meta Analysis ◽  
Factorial Analysis ◽  
Error Monitoring ◽  
Affective Dimension ◽  
Error Related Negativity ◽  
Error Positivity ◽  
Following Error ◽  
Analysis Of Error

Background: Evidence suggests that individuals with psychopathy display difficulties to adapt their behavior in accordance with the demands of the environment and show altered performance monitoring. However, studies investigating electrophysiological markers of error monitoring (e.g., the error-related negativity (ERN) and the error-positivity (Pe)) in this population reported mixed results. To explain discrepancies observed between studies, we hypothesized that psychopathy dimensions influence electrophysiological outcomes and we predicted that individuals with impulsive-antisocial features would display abnormal ERN compared to individuals with interpersonal-affective features. Methods: Based on the PRISMA guidelines, we conducted a systematic review and meta-analysis of studies investigating ERN and Pe components in individuals with psychopathy compared to controls. A factorial analysis was undertaken to investigate the role of psychopathy dimensions on ERN. Results: Among the 206 retrieved studies, 15 were included in the meta- analysis. Individuals with psychopathy (n = 817) showed a reduced ERN (Cohen's d = 0.18) and Pe amplitude (d = -0.22) compared to control. The factorial analysis indicates a dissociation regarding the dimensional construct of psychopathy. The impulsive-antisocial dimension was linked to reduced ERN amplitude (d = 0.22) whereas the interpersonal-affective dimension was related to increased ERN amplitude compare to controls (d = -0.17). Conclusion: Individuals with psychopathy displayed abnormal ERN and Pe amplitudes following error commission. In addition, models reported that individuals with psychopathic traits relating more specifically to the interpersonal-affective dimension shows efficient error-monitoring systems and increased ERN component while those with marked impulsive-antisocial dimension displayed decreased ERN and altered performance monitoring.

scholarly journals Misuse of medication in adult substance misuse services: a systematic review protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e047283
Author(s):  
Rosalind Gittins ◽  
Louise Missen ◽  
Ian Maidment
Keyword(s):  
Systematic Review ◽  
Substance Misuse ◽  
Data Extraction ◽  
Meta Analysis ◽  
Grey Literature ◽  
Opioid Analgesics ◽  
Physical And Mental Health ◽  
Qualitative Synthesis ◽  
Treatment Services ◽  
The Impact

IntroductionThere is a growing concern about the misuse of over the counter (OTC) and prescription only medication (POM) because of the impact on physical and mental health, drug interactions, overdoses and drug-related deaths. These medicines include opioid analgesics, anxiolytics such as pregabalin and diazepam and antidepressants. This protocol outlines how a systematic review will be undertaken (during June 2021), which aims to examine the literature on the pattern of OTC and POM misuse among adults who are accessing substance misuse treatment services. It will include the types of medication being taken, prevalence and demographic characteristics of people who access treatment services.Methods and analysisAn electronic search will be conducted on the Cochrane, OVID Medline, Pubmed, Scopus and Web of Science databases as well as grey literature. Two independent reviewers will conduct the initial title and abstract screenings, using predetermined criteria for inclusion and exclusion. If selected for inclusion, full-text data extraction will be conducted using a pilot-tested data extraction form. A third reviewer will resolve disagreements if consensus cannot be reached. Quality and risk of bias assessment will be conducted for all included studies. A qualitative synthesis and summary of the data will be provided. If possible, a meta-analysis with heterogeneity calculation will be conducted; otherwise, Synthesis Without Meta-analysis will be undertaken for quantitative data. The reporting of this protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.Ethics and disseminationEthical approval is not required. Findings will be peer reviewed, published and shared verbally, electronically and in print, with interested clinicians and policymakers.PROSPERO registration numberCRD42020135216.

scholarly journals P20-8 The impact of valproic acid on overall survival in patients with glioblastoma: A systematic review and meta-analysis

2021 ◽  
Vol 32 ◽  
pp. S340
Author(s):  
Charlotte A. Jonatan ◽  
Elizabeth Marcella ◽  
Jeannette Tandiono ◽  
Sharon Chen ◽  
Felix Wijovi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Valproic Acid ◽  
Overall Survival ◽  
Meta Analysis ◽  
The Impact

scholarly journals Apnoea–hypopnoea indices determined via continuous positive airway pressure (AHI-CPAPflow) versus those determined by polysomnography (AHI-PSGgold): a protocol for a systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e044499
Author(s):  
Fanny Bertelli ◽  
Carey Meredith Suehs ◽  
Jean Pierre Mallet ◽  
Marie Caroline Rotty ◽  
Jean Louis Pepin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Continuous Positive Airway Pressure ◽  
Airway Pressure ◽  
Sleep Disordered Breathing ◽  
Positive Airway Pressure ◽  
Meta Analysis ◽  
Sleep Apnoea ◽  
Obstructive Sleep ◽  
The Impact ◽  
Disordered Breathing

Introduction To date, continuous positive airway pressure (CPAP) remains the cornerstone of obstructive sleep apnoea treatment. CPAP data describing residual sleep-disordered breathing events (ie, the CPAP-measured apnoea–hypopnoea indices (AHI-CPAPflow)) is difficult to interpret because it is an entirely different metric than the polysomnography (PSG) measured AHI gold standard (AHI-PSGgold). Moreover, manufacturer definitions for apnoea and hypopnoea are not only different from those recommended for PSG scoring, but also different between manufacturers. In the context of CPAP initiation and widespread telemedicine at home to facilitate sleep apnoea care, there is a need for concrete evidence that AHI-CPAPflow can be used as a surrogate for AHI-PSGgold. Methods and analysis No published systematic review and meta-analysis (SRMA) has compared the accuracy of AHI-CPAPflow against AHI-PSGgold and the primary objective of this study is therefore to do so using published data. The secondary objectives are to similarly evaluate other sleep disordered breathing indices and to perform subgroup analyses focusing on the inclusion/exclusion of central apnoea patients, body mass index levels, CPAP device brands, pressure titration modes, use of a predetermined and fixed pressure level or not, and the impact of a 4% PSG desaturation criteria versus 3% PSG on accuracy. The Preferred Reporting Items for SRMA protocols statement guided study design. Randomised controlled trials and observational studies of adult patients (≥18 years old) treated by a CPAP device will be included. The CPAP intervention and PSG comparator must be performed synchronously. PSGs must be scored manually and follow the American Academy of Sleep Medicine guidelines (2007 AASM criteria or more recent). To assess the risk of bias in each study, the Quality Assessment of Diagnostic Accuracy Studies 2 tool will be used. Ethics and dissemination This protocol received ethics committee approval on 16 July 2020 (IRB_MTP_2020_07_2020000404) and results will be disseminated via peer-reviewed publications. PROSPERO/Trial registration numbers CRD42020159914/NCT04526366; Pre-results

Sign in / Sign up

Export Citation Format

Share Document